Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Noosa News20 hours agoBob Katter threatens to punch Nine reporter during ant-immigration press conference
-
Business23 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business20 hours agoDicker Data rides the AI trend to double digit growth
-
Business23 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy